Literature DB >> 28786335

Electronic visual analogue scales for pain, fatigue, anxiety and quality of life in people with multiple sclerosis using smartphone and tablet: a reliability and feasibility study.

D Kos1,2,3, J Raeymaekers1,4, A Van Remoortel5, M B D'hooghe5,6, G Nagels5,6, M D'Haeseleer5,6,7, E Peeters5,8, T Dams2, T Peeters2.   

Abstract

OBJECTIVE: To explore the reliability and feasibility of electronic visual analogue scales in people with multiple sclerosis (MS) and healthy individuals.
DESIGN: Cross-sectional observational study Setting: Clinical setting Subjects: Convenience sample of 52 people with MS and 52 matched healthy controls Interventions: NA Main measures: Participants scored 15 statements assessing fatigue, pain, anxiety and quality of life on an electronic visual analogue scale (eVAS), either using a smartphone or a tablet (randomly allocated). To check for test-retest reliability, statements were administered in two separate randomly ordered groups. Subjects completed a feasibility questionnaire.
RESULTS: Mean (SD) eVAS scores ranged from 35 (28.1) to 80 (22.1) in MS group, and from 57 (28.0) to 86 (13.2) in controls. Intra Class Correlations ranged from 0.73 to 0.95 in MS sample; 0.61 to 0.92 in controls. For most statements, Bland-Altman plots indicated no systematic error, but relatively large random error of the eVAS scores (exceeding 20mm). Considerable ceiling effects (i.e. better health) were found in healthy controls. Similar reliability was found among smartphone or tablet, different demographic groups and the experience-groups.
CONCLUSION: Electronic visual analogue scales are reliable and useful for people with MS to register fatigue, pain, anxiety and quality of life.

Entities:  

Keywords:  Multiple sclerosis; eVAS; electronic assessment; electronic visual analogue scale; feasibility; reliability; usability

Mesh:

Year:  2017        PMID: 28786335     DOI: 10.1177/0269215517692641

Source DB:  PubMed          Journal:  Clin Rehabil        ISSN: 0269-2155            Impact factor:   3.477


  6 in total

1.  Comparison of Clinical Efficacy and Recovery Effect between Lateral and Posterior Foraminoscopy and PELD in LDH Patients.

Authors:  Zhimin Zhang; Yaning Zhang; Chunxia Huang; Jianzhong Huo
Journal:  Contrast Media Mol Imaging       Date:  2022-06-25       Impact factor: 3.009

2.  Investigating and defining outcomes of suprapatellar versus infrapatellar intramedullary nailing of tibial shaft fractures: a protocol for a pilot randomised controlled trial.

Authors:  Simon Thwaites; Dominic Thewlis; Kelly Hall; Mark Rickman
Journal:  Pilot Feasibility Stud       Date:  2022-05-26

Review 3.  Mobile health (mHealth) usage, barriers, and technological considerations in persons with multiple sclerosis: a literature review.

Authors:  Elizabeth S Gromisch; Aaron P Turner; Jodie K Haselkorn; Albert C Lo; Thomas Agresta
Journal:  JAMIA Open       Date:  2020-12-15

Review 4.  Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Review of Clinical Manifestations as Foundations for Therapeutic Development.

Authors:  Spyros Papapetropoulos; Angela Pontius; Elizabeth Finger; Virginija Karrenbauer; David S Lynch; Matthew Brennan; Samantha Zappia; Wolfgang Koehler; Ludger Schoels; Stefanie N Hayer; Takuya Konno; Takeshi Ikeuchi; Troy Lund; Jennifer Orthmann-Murphy; Florian Eichler; Zbigniew K Wszolek
Journal:  Front Neurol       Date:  2022-02-03       Impact factor: 4.003

Review 5.  Measurement Comparability of Electronic and Paper Administration of Visual Analogue Scales: A Review of Published Studies.

Authors:  Bill Byrom; Celeste A Elash; Sonya Eremenco; Serge Bodart; Willie Muehlhausen; Jill V Platko; Chris Watson; Cindy Howry
Journal:  Ther Innov Regul Sci       Date:  2022-02-10       Impact factor: 1.778

6.  Reduction of fatigue and anger-hostility by the oral administration of 5-aminolevulinic acid phosphate: a randomized, double-blind, placebo-controlled, parallel study.

Authors:  Fumiko Higashikawa; Keishi Kanno; Akiko Ogata; Masanori Sugiyama
Journal:  Sci Rep       Date:  2020-09-29       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.